Genmab A/S

What they do

Genmab discovers and develops human antibody therapeutics for cancer and other diseases. The company operates through partnerships that generate milestones and royalties, as well as a growing portfolio of wholly-owned products. It is headquartered in Valby, Denmark, and listed on Nasdaq via American Depositary Shares.

Revenue drivers

• Royalties from partnered products — Genmab receives royalties on sales of medicines developed with partners such as Johnson & Johnson (DARZALEX) and AbbVie (epcoritamab). These royalties are a major recurring revenue source, though the filing does not quantify current-period amounts.
• Milestone payments — The company earns milestone payments when partners achieve development, regulatory, or commercial goals. These are episodic and can vary significantly year to year.
• Proprietary product sales — Genmab is transitioning to commercialize its own medicines, including epcoritamab (with AbbVie) and other pipeline candidates. Revenue from these products is expected to grow as launches expand, but no specific sales figures are provided in the excerpt.

Recent performance

The provided excerpt does not include specific financial results for fiscal year 2025. The filing is a Form 20-F for the year ended December 31, 2025, but detailed revenue, expense, and net income figures are absent from the source material. Therefore, recent performance cannot be summarized with figures from the available text.

Strategy

Genmab's stated strategy focuses on advancing a proprietary pipeline of antibody therapeutics while maintaining and expanding partnerships that provide royalties and milestones. The company aims to create and develop additional product candidates and to submit investigational new drug applications for preclinical assets. It also seeks to grow its commercial capabilities to support its own products. The excerpt does not disclose specific investment amounts or timelines.

Risks

• Dependence on partners — A significant portion of revenue comes from royalties and milestones tied to partners like Johnson & Johnson and AbbVie, so partner decisions or setbacks could materially impact results.
• Clinical and regulatory uncertainty — Product candidates may fail in clinical trials or not receive regulatory approval, which would delay or eliminate potential future revenue.
• Commercial execution risk — As Genmab expands into proprietary commercialization, it faces competition and the need to build sales and marketing infrastructure, which may not succeed as planned.
• Foreign exchange and international operations — As a Danish company with global operations, Genmab is exposed to currency fluctuations and regulatory complexities across multiple jurisdictions.

Outlook

Management's forward-looking statements emphasize expectations for sales growth, clinical development progress, and regulatory approvals of partnered and proprietary products. The company anticipates receiving future milestone payments and royalties, and it plans to advance its pipeline. Specific financial guidance is not provided in the excerpt.